Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. Catalona WJ, et al. Among authors: slawin km. J Urol. 2011 May;185(5):1650-5. doi: 10.1016/j.juro.2010.12.032. Epub 2011 Mar 17. J Urol. 2011. PMID: 21419439 Free PMC article. Clinical Trial.
The prostate health index selectively identifies clinically significant prostate cancer.
Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. Loeb S, et al. Among authors: slawin km. J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15. J Urol. 2015. PMID: 25463993 Free PMC article.
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG. Southwick PC, et al. Among authors: slawin km. J Urol. 1999 Oct;162(4):1346-51. J Urol. 1999. PMID: 10492194 Clinical Trial.
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, Richie JP, Patel A, Walsh PC, Scardino PT, Lange PH, deKernion JB, Southwick PC, Loveland KG, Parson RE, Gasior GH. Catalona WJ, et al. Among authors: slawin km. Urology. 2000 Mar;55(3):372-6. doi: 10.1016/s0090-4295(99)00547-6. Urology. 2000. PMID: 10699613 Clinical Trial.
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Catalona WJ, et al. Among authors: slawin km. JAMA. 1998 May 20;279(19):1542-7. doi: 10.1001/jama.279.19.1542. JAMA. 1998. PMID: 9605898 Clinical Trial.
140 results